
Global Breast Cancer Therapeutics Market Forecast to 2023; Led by AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer - ResearchAndMarkets.com
The "Global Breast Cancer Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The breast cancer therapeutics market will register a CAGR of close to 8% by 2023.
Emerging novel therapies to gain traction in the market
Therapies including combination therapies, vaccines, PARP inhibitors, and CDK inhibitors are emerging as innovative approaches to treat breasts cancer.
Rising number of patient supportive initiatives
To address the economic and emotional burden associated with cancer, manufacturers, governments, non-profit organizations, and healthcare providers are aiming at improving patient access to resources and bridge the substantial gaps in care.
Tendency of patients to prefer substitutes
Individuals with breast cancer often opt for mastectomy, lumpectomy, and radiation therapy to eliminate the tumor mass. However, efficient therapies including chemotherapy, and targeted and hormonal therapies are used to treat breast cancer. These surgeries act as substitutes and patients prefer these substitutes, which are expensive and can have a series of side effects.
Key Players
- AstraZeneca
- Eli Lilly
- F. Hoffmann-La Roche
- Novartis
- Pfizer
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Targeted therapy - Market size and forecast 2018-2023
- Hormonal therapy - Market size and forecast 2018-2023
- Chemotherapy - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
- Ductal carcinoma in situ
- Invasive Ductal Carcinoma
- Triple-negative breast cancer
- Inflammatory breast cancer
- Metastatic breast cancer
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca
- Eli Lilly
- F. Hoffmann-La Roche
- Novartis
- Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/vc65jq/global_breast?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190104005406/en/
Editor Details
-
Company:
- Business Wire
- Website: